Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

@article{Walsh2008TreatmentOA,
  title={Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.},
  author={Thomas J. Walsh and Elias J. Anaissie and David W. Denning and Raoul Herbrecht and Dimitrios P. Kontoyiannis and Kieren A Marr and Vicki A. Morrison and Brahm H. Segal and William J. Steinbach and David A. Stevens and Jo‐Anne H. van Burik and John R. Wingard and Thomas F. Patterson},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2008},
  volume={46 3},
  pages={
          327-60
        }
}
  • T. Walsh, E. Anaissie, T. Patterson
  • Published 1 February 2008
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Thomas J. Walsh, Elias J. Anaissie, David W. Denning, Raoul Herbrecht, Dimitrios P. Kontoyiannis, Kieren A. Marr, Vicki A. Morrison, Brahm H Segal, William J. Steinbach, David A. Stevens, Jo-Anne van Burik, John R. Wingard, and Thomas F. Patterson Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland; University of Arkansas for Medical Sciences, Little Rock; The University of Texas M. D. Anderson Cancer Center, Houston, and The University of Texas Health Science Center at San… 

Case report A lung cancer masquerader

TLDR
This research presents a novel, scalable and scalable approach that aims to provide real-time information about the immune system’s response to central giant cell transplantation.

How can we improve the management of fungal infections in immunocompromised patients?

TLDR
Jose A Vazquez’s research includes the epidemiology and management of fungal infections, the evaluation of newer antifungals, antIFungal resistance mechanisms and characterization of polymicrobial biofilm formation.

Switch in Immunocompromised Japanese Pediatric Patients 2

TLDR
This paper aims to provide a history of Hematology/Oncology and Regenerative Medicine in Japan and some of the aspects of its use in the treatment of cancer and other diseases.

Ask the Experts: How can we improve the management of fungal infections in immunocompromised patients?

TLDR
Jose A Vazquez’s research includes the epidemiology and management of fungal infections, the evaluation of newer antifungals, antIFungal resistance mechanisms and characterization of polymicrobial biofilm formation.

Aspergillus endocarditis in the era of new antifungals: major role for antigen detection.

Emergency management of life‐threatening haemoptysis due to invasive pulmonary aspergillosis in a sarcoidosis patient

TLDR
This research highlights the need to understand more fully the role of emotion in the decision-making process during surgery and the role that emotion plays in the planning and execution of neurosurgery procedures.

INVASIVE FUNGAL INFECTIONS IN ELDERLY PATIENTS RECEIVING ANTIBIOTIC TREATMENT: AN 8‐YEAR RETROSPECTIVE STUDY

1. Thomas JW, Elias JA, David WD et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Disease Society of America. Clin Infect Dis 2008;46:327–360. 2. Aubry A, Porcher R,

Multiple brain abscesses caused by Aspergillus fumigatus in a patient with systemic lupus erythematosus

* Division of Hematology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand. ** Division of Infectious Diseases and Tropical Medicine,

Efficacy and Safety Profile of Voriconazole as Salvage Therapy for Invasive Aspergillosis with Hematologic Diseases in Korea

TLDR
Gemella sanguinis is gram-positive, anaerobic, catalase and oxidase negative and should be examined as a cause of endocarditis.

Combination Antifungal Therapy for Invasive Aspergillosis

TLDR
The primary end point of this study was all-cause mortality at 6 weeks, rather than the composite global response, which had been shown to most closely approximate the deaths attributable to IA rather than deaths caused by underlying disease.
...

References

SHOWING 1-10 OF 371 REFERENCES

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

  • W. HughesD. Armstrong L. Young
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2002
TLDR
This work presents a meta-analyses of the immune system’s response to chemotherapy, which shows clear patterns of decline in the immune systems of patients diagnosed with central giant cell cancer.

Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution.

  • T. YeghenC. Kibbler S. Gillespie
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2000
TLDR
Investigation of hematologic malignancies and invasive pulmonary aspergillosis in patients identified between 1982 and 1995 showed a significant independent negative association between the radiological appearance of LISA and death from all causes.

Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference.

  • D. StevensR. Moss G. Mastella
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2003
TLDR
Virulence factors in Aspergillus that could aggravate these diseases, and particularly immunogenetic factors that could predispose persons to ABPA, were identified and diagnostic criteria that could provide a framework for monitoring were adopted.

Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria.

TLDR
Itraconazole is effective in many patients with aspergillosis, and this large series supports earlier conclusions that response rates are similar to those reported for amphotericin B.

Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes

TLDR
It is confirmed that mortality from invasive aspergillosis in severely immunosuppressed patients remains high even with standard amphotericin B, and new approaches and new therapies are needed to improve the outcome.

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.

  • J. WingardP. Kubilis J. Lister
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1999
TLDR
The data indicate that elevated creatinine levels during amphotericin B treatment are associated with a substantial risk for hemodialysis and a higher mortality rate, but the risks vary in different patient groups.

Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases.

  • W. SteinbachD. Benjamin T. Walsh
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2004
TLDR
Voriconazole is likely to be a better treatment choice for A. terreus infection than is a polyene, and decreased mortality at 12 weeks was observed in those patients who received voriconzole.

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

  • S. AşçıoğluJ. Rex T. Walsh
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2002
During the past several decades, there has been a steady increase in the frequency of opportunistic invasive fungal infections (IFIs) in immunocompromised patients. However, there is substantial
...